3rdPartyFeeds

Kroger Whipsaws After Q2 Earnings Beat: What's Next for the Grocery Giant?

On Thursday, Kroger (KR) reported second quarter earnings before the opening bell and shares fell by as much as 3% in intraday trading. Read More...

On Thursday, Kroger KR reported second quarter earnings before the opening bell and shares fell by as much as 3% in intraday trading. The company has struggled to stay in the green this year as they are down 7% year-to-date. The supermarket giant has been trying to increase its top and bottom lines through conventional initiatives. Let’s take a closer look at the company and how they might perform in the near future.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Company Overview and Q2 Performance ” data-reactid=”12″>Company Overview and Q2 Performance

The company was founded in 1883, incorporated in 1902, and is based in Cincinnati, Ohio. Kroger is one of the nation’s largest grocery retailers, operating over 2,700 stores under banners including Kroger, Dillon’s, Mariano’s, Food 4 Less, and more. The company also manufactures and processes certain food products that are sold in its supermarkets. The company’s supermarket stores operate under four formats: combo stores, multi-department stores, marketplace stores, and price impact warehouses. The combo, multi-department, and marketplace stores also offer fuel centers.

Kroger has recently undergone efforts to revive itself after Q1 where both earnings and revenue suffered Y/Y declines. Kroger introduced digital coupons, in-store pick up services for online orders, and smart shopping lists. In Q2, earnings jumped 7.32% to $0.44 per share and revenue jumped 0.55% to $28.2 billion; revenue growth was due to a 2.2% gain in same-store sales (excluding fuel) and broke a three-quarter streak of Y/Y top-line declines. Digital sales in Q2 slowed to 31% from more than 50% in the year ago quarter.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Outlook ” data-reactid=”15″>Outlook

Kroger reiterated its previous fiscal 2019 guidance of earnings between $2.15-$2.25 per share and same-store sales growth between 2%-2.25%. Our Q3 consensus estimates forecast earnings to increase 4.17% to $0.50 per share and for revenue to rally 2.08% to $28.25 billion. Our Key Company Metric estimates anticipate for supermarket sales (excluding fuel) to climb 4.73% to $24.9 billion. Looking ahead to their full fiscal year, estimates project earnings to pop 2.84% to $2.17 per share and for revenue to spike 1.35% to $122.8 billion.

Kroger is in the middle of a three-year plan to revive its business with investments in technology to better compete with companies like Walmart WMT, Target TGT, and Amazon AMZN. Walmart and Target both have reaped the benefits of improving their online presence and Kroger is looking to do the same. Its investments in its online presence seem to have paid off in Q2 as it drove revenue out of a three-quarter slump. However, continued stiff competition has made Kroger’s margins razor thin and will continue to be headwinds for the company moving forward. Kroger is listed as a Zacks Rank #4 (Sell) and has underperformed the above-mentioned stocks YTD.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now&gt;&gt;

” data-reactid=”25″>Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
&nbsp;
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
&nbsp;
Walmart Inc. (WMT) : Free Stock Analysis Report
&nbsp;
Target Corporation (TGT) : Free Stock Analysis Report
&nbsp;
The Kroger Co. (KR) : Free Stock Analysis Report
&nbsp;
To read this article on Zacks.com click here.
&nbsp;
Zacks Investment Research” data-reactid=”26″>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
 
Walmart Inc. (WMT) : Free Stock Analysis Report
 
Target Corporation (TGT) : Free Stock Analysis Report
 
The Kroger Co. (KR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Read More

About the author

admin

Add Comment

Click here to post a comment